Nevanac 3-Month Safety Study With QID Dosing
NCT00332774
·
clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
149
Enrollment
INDUSTRY
Sponsor class
Conditions
Cataract
Interventions
DRUG:
Nepafenac ophthalmic solution 0.1%
DRUG:
Ketorolac Tromethamine ophthalmic solution 0.4%
OTHER:
Nepafenac ophthalmic suspension vehicle
Sponsor
Alcon Research